SAN DIEGO--(BUSINESS WIRE)--Jan. 3, 2019--
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a leading insulin delivery
and diabetes technology company, today announced that Rebecca (Beckie)
Robertson was appointed as an independent member of its board of
directors.
“Beckie has an impressive track-record of helping medical device
companies scale in her roles as an engineer, entrepreneur, corporate
executive and board member,” said Kim Blickenstaff, president and CEO of
Tandem Diabetes Care. “Her experience with a diverse range of
technologies and business models, combined with her strategic vision,
further strengthens our Board as we prepare for the Company’s next phase
of growth.”
“It’s an exciting time to welcome Beckie to our Board,” said Dick Allen,
chairman of Tandem Diabetes Care. “She complements our board of
directors' skills and experiences, which we believe will prove valuable
as we execute on Tandem’s longer-term strategic growth initiatives in
support of our mission to improve the lives of people living with
diabetes.”
Ms. Robertson is a founder and managing director at Versant Ventures
where she specializes in investing in the areas of medical devices and
diagnostics. In addition, through Longridge Business Advisors, she
provides business advisory services. Prior to Versant, she served as
senior vice president at Chiron Diagnostics, a division of Chiron
Corporation, where she had responsibility for the critical care business
unit in addition to leading the division’s business development efforts.
Prior to joining Chiron, she was a co-founder and vice president at
Egis, a consumer products company, and held senior management positions
in operations and finance at Lifescan, a Johnson & Johnson Company. Ms.
Robertson holds a B.S. in chemical engineering from Cornell University.
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. (www.tandemdiabetes.com)
is a medical device company dedicated to improving the lives of people
with diabetes through relentless innovation and revolutionary customer
experience. The Company takes an innovative, user-centric approach to
the design, development and commercialization of products for people
with diabetes who use insulin. Tandem’s flagship product, the t:slim X2™
Insulin Pump, is capable of remote software updates using a personal
computer and features integrated continuous glucose monitoring. Tandem
is based in San Diego, California.
Follow Tandem Diabetes Care on Twitter @tandemdiabetes, use #tslimX2 and
$TNDM.
Follow Tandem Diabetes Care on Facebook at www.facebook.com/TandemDiabetes.
Follow
Tandem Diabetes Care on LinkedIn at www.linkedin.com/company/TandemDiabetes.
Tandem Diabetes Care is a registered trademark and t:slim X2 is a
trademark of Tandem Diabetes Care, Inc.
Forward Looking Statement
This press release contains “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended, that
concern matters that involve risks and uncertainties that could cause
actual results to differ materially from those anticipated or projected
in the forward-looking statements. These forward-looking statements
relate to, among other things, the anticipated future growth of the
Company. These statements are subject to numerous risks and
uncertainties, including our ability to obtain regulatory approval for
new products and products under development and the timing of any such
approvals; market acceptance of the Company’s existing products and
products under development by physicians and people with diabetes; the
Company’s ability to establish and sustain operations to support
international sales; the Company’s ability to meet increasing
operational and infrastructure requirements from higher customer
interest and a larger base of existing customers; as well as other risks
identified in our most recent Annual Report on Form 10-K and Quarterly
Reports on Form 10-Q, and other documents that we file with the
Securities and Exchange Commission. Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak only as
of the date of this release. Tandem undertakes no obligation to update
or review any forward-looking statement in this press release because of
new information, future events or other factors.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190103005639/en/
Source: Tandem Diabetes Care, Inc.
Media Contact:
Steve Sabicer
714-907-6264
ssabicer@thesabicergroup.com
Investor Contact:
Susan Morrison
858-366-6900 x7005
smorrison@tandemdiabetes.com
